Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. [electronic resource]
Producer: 20050119Description: 4639-44 p. digitalISSN:- 1078-0432
- Aged
- Aged, 80 and over
- Androstadienes -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Aromatase Inhibitors -- therapeutic use
- Breast Neoplasms -- genetics
- Celecoxib
- Cyclooxygenase Inhibitors -- therapeutic use
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Immunohistochemistry
- In Situ Hybridization, Fluorescence
- Letrozole
- Middle Aged
- Neoadjuvant Therapy
- Nitriles -- therapeutic use
- Prognosis
- Pyrazoles -- therapeutic use
- Receptor, ErbB-2 -- analysis
- Sulfonamides -- therapeutic use
- Treatment Outcome
- Triazoles -- therapeutic use
No physical items for this record
Publication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.